Lantern Pharma
LTRN
24 hedge funds and large institutions have $25.5M invested in Lantern Pharma in 2021 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
1,494% more capital invested
Capital invested by funds: $1.6M → $25.5M (+$23.9M)
467% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 3
140% more funds holding
Funds holding: 10 → 24 (+14)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
11.23% more ownership
Funds ownership: 1.33% → 12.57% (+11%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
Corriente Advisors
Fort Worth,
Texas
|
+$12.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.54M |
| 3 |
FHA
Flagship Harbor Advisors
Boston,
Massachusetts
|
+$2.59M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$803K |
| 5 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
+$789K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
-$499K |
| 2 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
-$210K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
-$193K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$17.3K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$9.31K |
LTRN Hedge Fund Activity: Q1 2021 in Review
24 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q1 2021, worth a combined $25.5M — up 1,494% from $1.6M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new LTRN positions and 3 closed out — a net gain of 14 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Corriente Advisors, opening a new position worth an estimated $12.5M. The largest seller was Voss Capital, exiting entirely with an estimated $499K sold.
- 24 institutional investors held Lantern Pharma (LTRN) as of Q1 2021, up from 10 in Q4 2020.
- Funds reported $25.5M of Lantern Pharma stock for Q1 2021, up 1,494% quarter-over-quarter.
- 17 funds opened new Lantern Pharma positions in Q1 2021 and 3 closed out, a net change of +14 holders.
- The largest Lantern Pharma buyer in Q1 2021 was Corriente Advisors, an estimated $12.5M added.
- The largest Lantern Pharma seller in Q1 2021 was Voss Capital, an estimated $499K sold.
Based on aggregated 13F filings for Q1 2021.